![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement
By
ASCO 2022 Conference Coverage
FEATURING
Ghassan Abou-Alfa
By
ASCO 2022 Conference Coverage
FEATURING
Ghassan Abou-Alfa
1,142 views
June 7, 2022
Login to view comments.
Click here to Login
GI